Shares of Sun Pharmaceuticals, India’s largest drug manufacturer, gained more than 50% over the last one year. In its latest results, the company also posted a 34% on year jump in Q4 profit. While the stock did decline slightly this week, pharma analysts are positive on the stock as the company has shown growth across key therapies. The biggest reason for optimism is Sun Pharma’s global specialty business, which exceeded USD1 billion in sales in
Related Posts
With data, we want to boost genomics, personalised medicines, manufacturing: WEF health chief
Shyam Bishen, chief of health and healthcare division, World Economic Forum; image credit: Twitter Synopsis The scars from the pandemic…
Cipla takeover: Torrent Pharma is gearing up to take over Cipla. Here’s why it’s a tightrope walk.
Synopsis If Torrent Pharma were to acquire Cipla, which is 2.5 times its size in sales, it would be a…
Remembering Novartis’ Ranjit Shahani: The pharma titan who walked a tightrope for India
Ranjit Shahani, former chief of Novartis Synopsis Ranjit Shahani will be remembered for his astute leadership and trademark calmness amid…
